Results: 206

Frequência da Covid-19 em pacientes com diagnóstico de lúpus eritematoso sistêmico

Objetivos: Determinar a frequência da Covid-19 em indivíduos com lúpus eritematoso sistêmico, bem como descrever aspectos relacionados a esse adoecimento. Métodos: Estudo observacional longitudinal, com 418 indivíduos, divididos em um grupo caso, composto de 224 portadores de doenças reumáticas...

Hydroxychloroquine with azithromycin in patients hospitalized for mild and moderate COVID-19

Braz. j. infect. dis; 25 (2), 2021
ABSTRACT Objectives: To assess the efficacy of hydroxychloroquine in combination with azithromycin in terms of clinical and biochemical outcomes in adult patients with COVID-19 hospitalized for acute respiratory distress syndrome (ARDS), and to describe the occurrence of adverse events. Method: Retrosp...

Ototoxic effects of hydroxychloroquine

Rev. Assoc. Med. Bras. (1992); 67 (supl.1), 2021
SUMMARY OBJECTIVE To present scientific evidence based on a systematic review of the literature (PRISMA), aiming to systematize evidence of the ototoxic effects of hydroxychloroquine (HCQ). METHODS The studies were selected using a combination based on the Medical Subject Headings (MeSH). The databases...

Use of hydroxychloroquine to prevent SARS-CoV-2 infection and treat mild COVID-19: a systematic review and meta-analysis

J. bras. pneumol; 47 (5), 2021
ABSTRACT Objective: Chloroquine or hydroxychloroquine has demonstrated no effect on the treatment of hospitalized COVID-19 patients. This study aimed to answer questions related to the use of hydroxychloroquine for pre-exposure or post-exposure prophylaxis of SARS-CoV-2 infection and in the treatment of...

El tratamiento del COVID-19 con hidroxicloroquina se asoció con aumento de la mortalidad y la cloroquina no mostró beneficios
Treatment of COVID-19 with hydroxychloroquine was associated with increased mortality and chloroquine showed no benefits

Cloroquina e hidroxicloroquina: medicamentos potencialmente inapropriados a idosos?

INTRODUÇÃO: Medicamentos potencialmente inapropriados a idosos (MPII) provocam mais efeitos adversos do que benefícios. Os critérios de Beers (CB) da American Geriatrics Society 2019 (CB2019) consideraram cinco situações clínicas como MPII. A análise de medicamentos por essas situações pode aux...

Síndrome antifosfolipídico, lupus eritematoso sistémico y tromboembolismo pulmonar
Antiphospholipid syndrome, systemic lupus erythematosus and pulmonary thromboembolism. Case presentation

Rev. cuba. reumatol; 22 (3), 2020
El síndrome antifosfolipídico o de Hughes, como también se le conoce, puede aparecer de manera aislada o asociado a otras enfermedades autoinmunes como el lupus eritematoso sistémico. La asociación de ambas entidades puede causar varias complicaciones, como el tromboembolismo pulmonar. Se presenta e...

Eficacia y seguridad de la cloroquina, la hidroxicloroquina y la azitromicina en pacientes con COVID-19. Resumen de evidencia

Resumen Introducción: hasta el momento, no se ha demostrado la efectividad de ningún tratamiento para afrontar la emergencia sanitaria por COVID-19. Objetivo: presentar la evidencia disponible respecto a la eficacia y seguridad del uso de cloroquina, hidroxicloroquina y azitromicina en la profilaxis ...

New benefits of hydroxychloroquine in pregnant women with systemic lupus erythematosus: a retrospective study in a tertiary centre

Abstract Objective: To determine pregnancy outcomes in women with systemic lupus erythematosus (SLE) who were treated with hydroxychloroquine in a tertiary center. Methods: A retrospective study involving pregnant women with SLE who had antenatal follow-up and delivery in between 1 January 2007 and 1 J...

Cloroquina e hidroxicloroquina en infección por COVID-19 (30 oct. 2020)

CONTEXTO CLÍNICO; La enfermedad por el Coronavirus 2019 (COVID–19, por su sigla en inglés Coronavirus Disease 2019) es una enfermedad respiratoria de humanos producida por un nuevo coronavirus identificado con la sigla SARS-CoV-2. El 11 de marzo de 2020 la Organización Mundial de la Salud (OMS) decl...